Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeFRA:N2U0 +9.64%11 EV-to-FCF is -20.93 as of Jul. 18, 2026. GuruFocus rates FRA:N2U0 with a GF Score™ of 11/100. The stock has 7 warning signs investors should review. Among 335 Biotechnology companies, Adlai Nortye ranks worse than 298507.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Adlai Nortye's Enterprise Value is €602.06 Mil.
Adlai Nortye's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-28.77 Mil. Therefore, Adlai Nortye's EV-to-FCF for today is -20.93.
The historical rank and industry rank for Adlai Nortye's EV-to-FCF or its related term are showing as below:
FRA:N2U0'
s EV-to-FCF Range Over the Past 10 Years
Min: -110.71 Med: -5.18 Max: 13.56
Current: -22.4
During the past 5 years, the highest EV-to-FCF of Adlai Nortye was 13.56. The lowest was -110.71. And the median was -5.18.
FRA:N2U0's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.51
vs FRA:N2U0: -22.40
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Adlai Nortye's PE Ratio (TTM) for today is calculated as:
Adlai Nortye's share price for today is €9.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adlai Nortye's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.955.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Adlai Nortye EV-to-FCF Related Terms
Adlai Nortye EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adlai Nortye's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's EV-to-FCF falls into.
Adlai Nortye's current Enterprise Value is €602.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adlai Nortye's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-28.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (FRA:N2U0) has a EV-to-FCF of -20.93 as of Jul. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adlai Nortye and its competitors. According to the industry distribution chart, Adlai Nortye ranks #999999 out of 335 companies in the Biotechnology industry.
Is Adlai Nortye's EV-to-FCF too high?
Adlai Nortye's current EV-to-FCF is -20.93. Based on the distribution chart, Adlai Nortye ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adlai Nortye has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Adlai Nortye's EV-to-FCF compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #999999 out of 335 companies for EV-to-FCF. This places Adlai Nortye in the lower half of its industry. The industry median EV-to-FCF is 15.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.51, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current EV-to-FCF is -20.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (FRA:N2U0) has a current EV-to-FCF of -20.93. The current EV-to-FCF is -20.93. Adlai Nortye's overall GF Score™ is 11/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Adlai Nortye (FRA:N2U0), the current EV-to-FCF is -20.93 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
11GF Score
Get the complete analysis for FRA:N2U0
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:N2U0 has been successfully added to your 
